-
Nat Commun: SynNotch CAR-T cells targeting GD2 and B7H3 are expected to treat neuroblastoma
Time of Update: 2021-03-04
Now, in a new study, researchers at Children's Hospital Los Angeles have developed an improved version of car-T cells that show hope in targeting neuroblastoma: killing cancer cells more effectively without harming healthy brain tissue.
-
Advanced kidney cancer "immune and targeted" first-line treatment! The Opdivo-Cabometyx program was approved by the FDA and beats Sutt!
Time of Update: 2021-03-04
the Opdivo and Cabometyx "Immune plus Targeting" combinations have been approved through the Priority Review Program and the Real-Time Oncology Review (RTOR) pilot project for all international metastatic kidney cancer database alliance (IMDC) risk classifications, providing an important, new first-line treatment for the previously untreated group of patients with advanced or metastatic RCC.
-
Paboli pearl monoantigen and beval pearl monotherapy treat relapse high-level glioma
Time of Update: 2021-03-04
Solmaz Sahebjam, of Moffitt Cancer Center in Tampa, Florida, USA, to assess the paboliju monoantigen (all-human immunoglobulin IgG4 monoclonal antibody inhibitor) against PD-1 In combined with Beval bead monoanti, hypofraction stereotatic radiotherapy (hypofractionation stereotactic irradiation, HFSRT) treats the safety and toad of HGG patients, as well as initial efficacy, and recommends appropriate dosages.
-
Colorectal Cancer (CRC) Precision Medicine! Mesa East Keytruda is approved by the European Union: first-line treatment MSI-H/dMMR metastasis CRC!
Time of Update: 2021-03-04
January 26, 2021 // -- Merck Co) recently announced that the European Commission (EC) has approved the anti-PD-1 therapy Keytruda (Corida, generic name: pembrolizumab, Pabliju monotherapy), as a single-drug therapy, first-line treatment of metastatic microsatellite instability high (MSI-H) or mismatch repair defects (dMMR) colorectal cancer (mCRC) adult patients.
-
Study on the application of human small brain organs in myeloma
Time of Update: 2021-03-04
the authors successfully built a type 3 MB model in mice using different genetic combinations to trans-infect human brain organs.
-
The brain structure area closely related to intellectual change after radiotherapy in children with brain tumors
Time of Update: 2021-03-03
S. Tsang of the Department of Radiology at Princess Margaret Cancer Center in Toronto, Canada, and others studied the response and cognitive changes to radiation therapy in different brain structure regions, the results of which were published online September 2020 in Neuro-Oncology.
-
Scientists reveal the physical properties behind tumor growth!
Time of Update: 2021-03-03
January 30, 2021 // -- A recent study published in the international magazine Biosystems entitled "Cell and extracellular matrix matrix theory and its ideas for tumorigenesis", from Duke Scientists at universities and other institutions have developed a new strategy to predict tumor growth; instead of focusing on the biological mechanisms of cell growth, researchers are using thermodynamics and the physical space of tumor expansion to predict the process of metastatic lumps from individual cells.
-
Nature sub-journal interpretation! Spontaneous cell fusion may amplify genetic diversity in tumors!
Time of Update: 2021-03-03
2021 // -- Scientists from the Moffitt Cancer Research Center and others have found that spontaneous cell genetic diversity within tumors may be amplified by a study published in the international jo
-
Immunotherapy for esophageal cancer! Baiji Shenzhou Bazean ® esophageal squamous cell carcinoma (ESCC) global phase 3 clinical success: significantly extended survival!
Time of Update: 2021-03-03
January 29, 2021 // -- BeiGene recently announced that the EVALUATION 302 Global Phase 3 clinical trial evaluating the treatment of esophageal squamous cell carcinoma (ESCC) against the anti-PD-1 antibody Bazean® RATIONALE 302 is a randomized, open-label, multi-center Global Phase 3 clinical trial (NCT03430843) conducted in patients with late-stage non-removable or metastasis ESCC who have previously underwent systemic therapy and evaluated the efficacy and safety of the chemotherapy chosen by the researchers®.
-
Science Read! Scientists have solved a hundred-year mystery about cancer!
Time of Update: 2021-03-03
January 30, 2021 // -- Scientists from the Memorial Sloan Kettering Cancer Center and others have solved a 100-year-old mystery about cancer in a recent study published in the international journal Science entitled "Glycolysis fuels phosphonositide 3-kinase signaling to Bolster T cell immunity".
-
Prof. Zhai Baocai: The survival period has doubled, and the "T-A" immunotherapy has promoted a leap forward in the systematic treatment of advanced liver cancer
Time of Update: 2021-03-03
The world's only first-line immunologic combination therapy approved for non-excision of hepatocellular carcinoma treatment at present, Atiliju single anti-combination beva bead monoantimmune (the "T-A" program) published the latest results of the study, after the "T-A" treatment of patients with a total survival of 19.2 months, of which the Chinese sub-group of patients with a medium total survival of 24.0 months, bringing new hope for patients with advanced liver cancer.
-
Latest Research Advances in CAR-T Cell Therapy (No. 19)
Time of Update: 2021-03-02
January 31, 2021 // ---CAR-T (Chimeric Antigen Receptor T-Cell Immunotherapy), a chimeric antigen receptor T-cell immunotherapy. therapy is a new type of cell therapy that has been available for man
-
First-line immunotherapy for lung cancer 1 <1! Merca East Head-to-Head Phase 3 Study: Add Yeervoy to Keytruda, no increase in benefits, increased toxicity!
Time of Update: 2021-03-02
KEYNOTE-598 is the first head-to-head study to answer the question of whether, in some patients with metastasis non-small cell lung cancer, the combined Keytruda and Yervoy provide additional clinical benefits over the treatment of Keytruda alone.
-
The effect of Paboliju monoantigen or combined beva bead monoantigen treatment of recurrence GBM was not good
Time of Update: 2021-02-28
VEGF inhibitor bevacizumab can prolong the progression-free survival of relapsed glioblastoma, and beva bead monoantigen can also inhibit tumor growth through a variety of mechanisms.
study, the researchers found that patients with relapsed GBM had good resistance to Pabliju monodratives or combined beval beads, but had limited clinical efficacy.
-
Change clinical practice! Opdivo assists in the treatment of muscle-immersive urethra cancer (MIUC): significantly extends disease-free survival!
Time of Update: 2021-02-27
2021 // -- BMS recently announced the results of the key Phase 3 CheckMate-274 trial. the trial evaluated opdivo (Odivo, generic name: nivolumab, Navuliyu monoanti) as an auxiliary (postoperative) th
-
Cell: Tumor immunotherapy can be used to treat malignant brain cancer
Time of Update: 2021-02-27
February 15, 2021 /--- -- Scientists have identified a new target for a potentially malignant brain tumor immunotherapy, according to a recent paper published in the journal Cell.
-
CD19 CAR-T therapy! Gilead Yescarta's use of corticosteroids before infusion can reduce cytokine release syndrome and neurological events!
Time of Update: 2021-02-27
In the ZUMA-1 trial of a new safety management queue (queue 6), the primary purpose was to assess the effects of preventive use of corticosteroids and early use of corticosteroids and/or tocilizumab (toad monoantigen) therapy on the occurrence and severity of cytokine release syndrome (CRS) and neural events.
-
EMBO Rep: Scientists have identified new drug targets that promise to treat hepatocellular carcinoma!
Time of Update: 2021-02-27
Photo Source: Chong Teik TAN Hepatocellular Carcinoma (HCC) is the leading form of liver cancer and the fourth leading cause of cancer-related death in the global population, and although researchers have identified a variety of risk factors and genetic variants that induce hepatocellular carcinoma, the prognosis is still poor due to the limited treatment available to patients.
-
First-line treatment of kidney cancer: Mercadon / Weishi "Immunity and Targeting" combination Keytruda and Lenvima Phase 3 Clinical: Efficacy beats Schoinidini!
Time of Update: 2021-02-27
the study is evaluating the anti-PD-1 therapy Keytruda (Corida ®, common name: pembrolizumab, Pabli pearl monoantigen) and oral polysuper tyrosine kinase inhibitor Lenvima First-line treatment of patients with advanced renal cell carcinoma (RCC) and comparison with the Lenvima®Ivimos and sunitinib programmes.
-
Triple Negative Breast Cancer (TNBC) Immunotherapy! Mercedon Keytruda's treatment of high-risk early TNBC was rejected by the FDA committee!
Time of Update: 2021-02-27
In another major endpoint, event-free lifetime (EFS), median follow-up was 15.5 months, and the Keytruda programme showed a favourable trend in EFS compared to the chemotherapy-placebo programme, reducing the risk of progression and secondary recurrence of new secondary diseases by 37% (HR=0.63 (95% CI: 0.43-0.93)." it's worth noting that, based on this study data, Keytruda is the first anti-PD-1 therapy to show a statistically significant improvement in pCR as a new complementary therapy for TNBC (regardless of PD-L1 status).
